Carisoprodol
Carisoprodol (Soma) is a DEA Schedule IV centrally-acting muscle relaxant approved for short-term relief of acute musculoskeletal pain. It is a prodrug that is extensively metabolized to meprobamate — a barbiturate-like sedative-anxiolytic that was formerly used for anxiety treatment and is itself a Schedule IV controlled substance. This meprobamate conversion is primarily responsible for carisoprodol's abuse potential, sedation, and physical dependence. Among muscle relaxants, carisoprodol carries the highest recognized abuse risk and should generally be reserved for short-term use when other options are inadequate. Abrupt discontinuation after chronic use can precipitate a withdrawal syndrome including seizures.
Uses & FDA Indications
Carisoprodol is FDA-approved as an adjunct to rest, physical therapy, and other treatments for relief of discomfort associated with acute, painful musculoskeletal conditions in adults. The key qualifier is acute — it is intended for short-term use, generally no longer than two to three weeks, because there is no evidence supporting longer-term benefit and substantial evidence of increasing harm with prolonged use.
Clinical settings where carisoprodol may be used include acute low back pain, muscle strains and sprains, and similar short-duration musculoskeletal injuries. It provides modest analgesic benefit primarily through sedation and muscle relaxation mediated by its CNS effects rather than any direct peripheral muscle action.
Importantly, carisoprodol is not approved for chronic pain, fibromyalgia, spasticity from neurological conditions (multiple sclerosis, spinal cord injury — where baclofen is typically preferred), or as maintenance therapy. The FDA label explicitly limits use to acute painful conditions with a clear expectation of short-term resolution.
How It Works
Carisoprodol's mechanism is not fully characterized. It does not directly relax skeletal muscle at the neuromuscular junction. Instead, it acts centrally in the brain and spinal cord to produce sedation and to interrupt interneuronal communication in the descending reticular formation and spinal cord — effects that may indirectly reduce muscle spasm perception.
Carisoprodol is rapidly absorbed and extensively metabolized by CYP2C19 in the liver to meprobamate. Meprobamate is a carbamate anxiolytic that potentiates GABA-A receptor activity, producing CNS depression, sedation, and anxiolysis similar to benzodiazepines and barbiturates. Meprobamate accumulates with repeated carisoprodol dosing (its half-life is approximately 10 hours versus ~2 hours for carisoprodol) and is considered the primary driver of the drug's abuse potential, dependence, and withdrawal syndrome.
CYP2C19 poor metabolizers — who cannot efficiently convert carisoprodol to meprobamate — accumulate substantially higher carisoprodol levels (4–10 times normal). This genetic variation may contribute to variable individual responses to the drug. Notably, meprobamate was itself once a widely-prescribed anxiolytic in the 1950s–1960s, known by brand names Miltown and Equanil, before it was supplanted by benzodiazepines due to its dependence risk.
ABUSE, MISUSE, AND DEPENDENCE: Carisoprodol is a Schedule IV controlled substance. Misuse of carisoprodol — alone or in combination with opioids and benzodiazepines — is associated with emergency department visits and deaths. Abrupt discontinuation after prolonged use can cause a withdrawal syndrome including insomnia, anxiety, tremors, hallucinations, and seizures. Use only as prescribed, for the shortest duration necessary, and taper when discontinuing after extended use.
Side Effects
Common
- Drowsiness/sedation — the most common effect; impairs driving, machinery operation, and cognitive function; enhanced by alcohol and other CNS depressants
- Dizziness, headache — particularly at initiation
- Ataxia — incoordination; increases fall risk, especially in elderly
- Irritability, agitation — paradoxical CNS stimulation reported in some patients
- Tachycardia — elevated heart rate reported
- Nausea, vomiting, epigastric distress
Serious
- Physical dependence and withdrawal — with prolonged use; abrupt cessation can cause anxiety, insomnia, tremors, hallucinations, and generalized seizures (meprobamate withdrawal)
- CNS depression / overdose — potentially fatal, especially when combined with opioids, benzodiazepines, or alcohol; respiratory depression is the primary cause of death in carisoprodol overdose
- Idiosyncratic reactions — with the first dose: extreme weakness, transient quadriplegia, temporary vision loss, euphoria, ataxia, or confusion have been reported. If these occur, the drug should be discontinued.
- Seizures — in overdose or during withdrawal
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Opioid Analgesics (oxycodone, hydrocodone, morphine) | Additive CNS and respiratory depression. The combination of carisoprodol, an opioid, and a benzodiazepine ("Holy Trinity") is associated with diversion and drug-related overdose deaths. | High — avoid combination; boxed warnings apply; monitor closely if unavoidable |
| Benzodiazepines (diazepam, alprazolam, clonazepam) | Synergistic CNS and respiratory depression. Combined sedation substantially increases overdose and aspiration risk. | High — avoid concurrent use; if used together, use lowest doses for shortest duration |
| Alcohol | Potentiates CNS depression from both carisoprodol and meprobamate. Impairs judgment, coordination, and increases sedation risk significantly. | High — contraindicated during carisoprodol use; counsel explicitly |
| CYP2C19 Inhibitors (omeprazole, fluvoxamine, fluoxetine) | Inhibit carisoprodol-to-meprobamate conversion, causing carisoprodol accumulation. Clinical significance varies by individual baseline CYP2C19 activity. | Moderate — monitor for enhanced or unusual CNS effects |
| Other CNS Depressants (antihistamines, antipsychotics, tricyclic antidepressants) | Additive sedation and CNS depression. Increases fall risk and cognitive impairment. | Moderate — avoid unnecessary combinations; counsel on impaired driving |
Warnings & Contraindications
Contraindications
- Acute intermittent porphyria — carisoprodol and meprobamate can precipitate porphyric crises
- Hypersensitivity to carisoprodol, meprobamate, or other carbamate compounds
- History of acute idiosyncratic reaction to first dose
Duration of Use
The FDA-approved labeling restricts carisoprodol to short-term use — up to two to three weeks. There is no adequate evidence that the drug provides benefit beyond this period, and the risk of dependence, withdrawal, and misuse increases substantially with longer duration. Prescribers should reassess the need for continued therapy at each visit. Long-term use should be avoided, and if a patient has been using carisoprodol chronically, gradual tapering rather than abrupt discontinuation is necessary to prevent withdrawal seizures.
Use in Elderly Patients
The American Geriatrics Society Beers Criteria lists all muscle relaxants including carisoprodol as potentially inappropriate medications for adults 65 years and older. Older adults have increased sensitivity to CNS depressants, higher fall risk, and reduced clearance of carisoprodol and meprobamate. The risk-benefit ratio is generally unfavorable in elderly patients; non-pharmacological approaches and physical therapy are strongly preferred.
Pregnancy and Lactation
Carisoprodol crosses the placenta and is present in breast milk. It should not be used in pregnant or breastfeeding women. Meprobamate, the active metabolite, concentrates in breast milk at levels two to four times maternal plasma levels.
Check for CNS depression interactions or opioid combination risks with carisoprodol.
Check Drug Interactions →Frequently Asked Questions
Is carisoprodol a controlled substance?
Yes. Carisoprodol (Soma) is classified as a Schedule IV controlled substance by the DEA, placing it in the same regulatory category as benzodiazepines and other drugs with recognized abuse and dependence potential. It was added to Schedule IV in 2012 after years of mounting evidence of widespread misuse. Its metabolite, meprobamate (which also has CNS depressant and anxiolytic properties), is independently Schedule IV. Many states have additional restrictions beyond federal scheduling, including mandatory prescription drug monitoring program (PDMP) reporting and limits on prescription quantities and refills.
Why is carisoprodol considered high risk for abuse?
Carisoprodol carries among the highest abuse potential of all muscle relaxants for several reasons: First, it is metabolized to meprobamate, a barbiturate-like anxiolytic that acts on GABA-A receptors and produces sedation, euphoria, and anxiolysis — effects that make it reinforcing and prone to misuse. Second, physical dependence develops with repeated use, and abrupt discontinuation after prolonged use can cause a withdrawal syndrome that includes anxiety, insomnia, tremors, and in severe cases, seizures. Third, it is frequently combined with opioids and benzodiazepines ("the Holy Trinity" of drug diversion) by individuals seeking to enhance sedative effects, a combination associated with significant overdose deaths.
How does carisoprodol compare to cyclobenzaprine?
Both carisoprodol and cyclobenzaprine are centrally-acting muscle relaxants used for short-term acute musculoskeletal pain, but they differ substantially in their mechanisms and risk profiles. Cyclobenzaprine is structurally related to tricyclic antidepressants and works primarily through central noradrenergic mechanisms; it is not a controlled substance and has no significant abuse potential, though it causes sedation and has anticholinergic side effects. Carisoprodol is a controlled substance with significant abuse, dependence, and withdrawal risk due to its conversion to meprobamate. Most guidelines and clinical authorities prefer cyclobenzaprine, baclofen, or methocarbamol over carisoprodol when a muscle relaxant is needed, specifically because of carisoprodol's higher abuse risk.